Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial
Annals of the Rheumatic Diseases · 2026
DOI: 10.1016/j.ard.2026.01.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026. Verfasst von Jeremy A Hawkins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, School of Public Health, Portland, OR, USA. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Abatacept, Antirheumatic Agents, Herpes Zoster Vaccine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Center for Advancing Translational Sciences, Bristol-Myers Squibb.
Abstract (Originalsprache)
OBJECTIVES: The objective of the study is to evaluate the safety and immunogenicity of the recombinant zoster vaccine (RZV) in patients with rheumatoid arthritis (RA) using abatacept. METHODS: We randomised 70 participants to receive 2 doses of RZV or placebo 8 weeks apart. The primary immunologic endpoint was the proportion of participants developing a ≥4-fold increase in anti-glycoprotein E (gE) immunoglobulin (Ig)G antibodies (humoral responders) and those developing a ≥2-fold increase in interferon gamma (IFN-γ)+ or interleukin-2 (IL-2)+ gE-specific spot-forming cells (cellular responders), at week 12 (ie, 4 weeks post-second RZV dose). The secondary immunologic endpoint was the geometric mean fold rise (GMFR) in cellular and humoral vaccine responses. For safety, we solicited adverse events following each dose, serious adverse events (SAEs) during the 52-week study period, and evaluated the potential for RA flares by assessing pre- and postvaccination Disease activity score-28 for rheumatoid arthritis with erythrocyte sedimentation rate, Clinical Disease Activity Index (CDAI), and Outcome Measures in Rheumatology (OMERACT) rheumatoid arthritis flare questionnaire (RA-FQ) scores. RESULTS: Fifty-six (75%) participants received RZV, and 14 (25%) received a placebo. Among those receiving RZV, only 22 (42.3%) of participants surpassed the 4-fold threshold for humoral response, and anti-gE IgG GMFR at week 12 was 4.55 (3.16, 6.47). Only 5 (10.2%) patients with RZV mounted cellular responses. Six SAEs were noted, and the proportion of patients with RA flare was similar between RZV and placebo groups (38 [68%] vs 9 [64%]). CONCLUSIONS: Our data suggest that RZV is safe in patients with RA using abatacept, but that the vaccine response is attenuated in such patients. Further studies should be undertaken to evaluate whether holding abatacept around the time of vaccination would improve vaccine response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, School of Public Health, Portland, OR, USA.
- Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Departments of Pediatrics, Medicine, and Pathology, University of Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
- Arthritis Associates, Hixson, TN, USA.
- St. Luke's Health System, Rheumatology, Boise, ID, USA.
- Charleston Area Medical Center, Charleston, WV, USA.
Förderung
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Advancing Translational Sciences
- Bristol-Myers Squibb
- National Institutes of Health
Zitieren
APA
Hawkins, J. A., Curtis, J. R., Weinberg, A., Siegel, S. A. R., Huffstutter, J. E., Loveless, J., Gharib, S., Reddy, S., Sinha, J., Ridley, D., Messaoudi, I., Park, J. K., Lee, E. B., & Winthrop, K. L. (2026). Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2026.01.002
Vancouver
Hawkins JA, Curtis JR, Weinberg A, Siegel SAR, Huffstutter JE, Loveless J, et al. Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial. Annals of the Rheumatic Diseases. 2026. doi:10.1016/j.ard.2026.01.002
BibTeX
@article{Hawkins2026,
author = {Hawkins, Jeremy A and Curtis, Jeffrey R and Weinberg, Adriana and Siegel, Sarah A R and Huffstutter, Joseph E and Loveless, James and Gharib, Suzanne and Reddy, Shanmugapriya and Sinha, Jayashree and Ridley, David and Messaoudi, Ilhem and Park, Jin Kyun and Lee, Eun Bong and Winthrop, Kevin L},
title = {Safety and immunogenicity of the recombinant zoster vaccine in patients with rheumatoid arthritis using abatacept: a pilot multicentre, double-blind, randomised controlled trial},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
doi = {10.1016/j.ard.2026.01.002}
}
EUVIMED